Summary
Core view: Acutaas Chemicals grew Q1 FY27 revenue 48.5% and PAT 70.4% year-on-year, but both fell sharply quarter-on-quarter (revenue -25.3%, PAT -44.2%) from an exceptional Q4 FY26. At about 74x trailing earnings, the valuation already assumes continued strong growth, so the sequential decline is a meaningful signal to watch rather than a footnote.
Acutaas Chemicals (formerly Ami Organics) manufactures specialty and pharma intermediates and APIs, serving both regulated pharma and broader specialty-chemicals customers.
Q1 FY27 Snapshot
Revenue₹331.5 Cr+48.5% YoY, -25.3% QoQ
PAT₹75 Cr+70.4% YoY, -44.2% QoQ
EBITDA margin~34%Q1 FY27
EPS (Q1)₹9.04vs ₹16.04 in Q4 FY26
| Metric | Q4 FY26 | Q1 FY27 |
|---|---|---|
| Total income | ₹443.9 Cr | ₹331.5 Cr |
| EPS | ₹16.04 | ₹9.04 |
Business Quality And Mix
Strengths
- Strong YoY growth in both revenue (+48.5%) and PAT (+70.4%).
- High ~34% operating margin reflects specialty/pharma-intermediate positioning.
- Diversified across pharma and specialty-chemicals end markets.
- History as a well-regarded specialty-chemicals manufacturer (formerly Ami Organics).
Constraints
- Sharp sequential decline (-25.3% revenue, -44.2% PAT) from an exceptional Q4 FY26.
- Trailing P/E of about 74x is rich and prices in continued strong growth.
- Specialty/pharma-intermediate demand can be lumpy, tied to customer order cycles.
- 52-week range of ₹1,290-₹3,735 shows high stock volatility.
Growth Drivers And Capacity Economics
EBITDA margin~34%Q1 FY27
Dividend₹2.5/shareEx-date 17 Sep 2026
52-week range₹1,290-₹3,735High volatility
Growth has been driven by strong demand across pharma and specialty-chemical intermediates, though the sharp sequential decline this quarter suggests some lumpiness in order timing rather than a smooth linear growth trajectory.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Growth sustainability | Continue YoY growth | 48.5% YoY growth this quarter is strong, but the sharp QoQ decline suggests order-timing lumpiness that management has not specifically explained in the cited sources. |
| Margin | Sustain a low-to-mid-30s% EBITDA margin | Roughly consistent with the Q1 FY27 print, though a formal margin target was not identified in the cited sources. |
| Valuation discipline | Not a management guidance item | At ~74x trailing P/E, the stock already prices in continued strong growth; any slowdown could compress the multiple materially. |
Financial Quality
Trailing P/E~74xRich valuation
EBITDA margin~34%Q1 FY27
Sequential revenue change-25.3% QoQOff an exceptional Q4 base
Sequential PAT change-44.2% QoQLarger decline than revenue
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | PAT +70.4% YoY but -44.2% QoQ | The YoY comparison is strong, but the scale of the sequential decline (steeper than the revenue decline) suggests some margin or mix pressure this quarter versus Q4 FY26. |
| Valuation risk | ~74x trailing P/E | A rich multiple leaves little room for a growth disappointment; the sequential decline is a signal worth monitoring closely. |
| Volatility | 52-week range ₹1,290-₹3,735 | The wide range reflects a stock highly sensitive to quarterly results and sentiment shifts. |
Valuation
Key Risks
- Order-timing lumpiness causing large sequential swings.
- Rich ~74x trailing valuation vulnerable to any growth disappointment.
- Customer concentration in specialty/pharma intermediates.
- Raw-material and regulatory compliance risk.
- High stock volatility (52-week range ₹1,290-₹3,735).
Projection: Next 2-4 Quarters
Investor Watchlist
- Sequential revenue and PAT trend versus the Q1 FY27 dip.
- EBITDA margin stability.
- Customer and product-category concentration, if disclosed.
- Valuation multiple relative to growth delivery.
- Dividend continuity.